President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years.
Read the best of our journalism: https://www.thetimes.com/
Subscribe to The Times and The Sunday Times YouTube channel: https://www.youtube.com/subscription_center?add_user=timesonlinevideo
Find us on Facebook: https://www.facebook.com/timesandsundaytimes/
Find us on X: https://x.com/thetimes
Find us on Instagram: https://www.instagram.com/thetimes/
